Srnalytics

srnalytics uses small rna to help clinicians understand, diagnose and predict drug response for the 95% of disease that can't be assessed by dna alone. we have developed a unique platform for the identification of biomarkers from small rna sequencing data. this technology has the ability to de-risk drug development, accelerate programs, and identify novel drug targets srnalytics, in collaboration with academic collaborators, has generated proof-of-concept for our technology platform and hold intellectual property rights in huntington's, alzheimer's, and parkinson's disease. we are seeking industry partners from all stages of clinical development to strategically develop our biomarker technology with your drug product. srnalytics aims to collaborate with pharma, biotech and cro's and help deliver life-saving therapeutics in shortened time frames with longer exclusivity periods.